Aerovate Therapeutics Announces Third Quarter 2021 Financial Results
WALTHAM, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced our financial results for the quarter ended September 30, 2021, and recent events.
“We continue to make progress with clinical trial sites to participate in our global Phase 2b/3 trial of AV-101 in PAH and expect to initiate enrollment this year in the Phase 2b portion of the trial,” said Timothy Noyes, chief executive officer of Aerovate. “We are also pleased with investor support for our IPO, which we believe provides sufficient capital to fund Aerovate into the second half of 2025.”
Raised $126.9 Million in Net Proceeds from IPO. On July 2, 2021, we closed our initial public offering (IPO) raising gross proceeds of $139.8 million, which included full exercise of the underwriters’ option to purchase additional shares of common stock, at a public offering price of $14.00 per share. We raised net proceeds of approximately $126.9 million after deducting underwriting discounts and commissions and other offering expenses payable by us.
Preparation Continues for Global Phase 2b/3 Clinical Trial. We continued preparing for the initiation of our Phase 2b/3 trial of AV-101, our dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, or PAH, a devastating disease impacting approximately 70,000 people in the United States and Europe. Drug supply has been manufactured and we have begun scheduling site activation meetings in the United States. We anticipate including experienced PAH centers from more than 20 countries in our Phase 2b/3 trial. We have obtained orphan drug designation from the U.S. Food and Drug Administration and the European Medicines Agency for AV-101 for the treatment of PAH in the United States and the European Union.
Third Quarter 2021 Financial Results
Cash and cash equivalents totaled $180.9 million as of September 30, 2021, compared to $59.2 million as of June 30, 2021. The increase was primarily driven by net proceeds of $126.9 million from the Company’s IPO, which closed on July 2, 2021, offset by operational costs for the three-month period ending September 30, 2021.
R&D expenses: Research and development (R&D) expenses for the third quarter of 2021 were $3.4 million as compared to $2.0 million for the third quarter of 2020. The increase in R&D expenses was due primarily to increased clinical trial costs and manufacturing costs in the third quarter of 2021 as compared to the third quarter of 2020.
G&A expenses: General and administrative (G&A) expenses for the third quarter of 2021 were $2.8 million as compared to $0.3 million for the third quarter of 2020. The increase in G&A expenses was due primarily to increased headcount-related costs, insurance costs, legal fees, accounting fees and consulting expenses in the third quarter of 2021 as compared to the third quarter of 2020.
Net loss: Net loss for the third quarter of 2021 was $6.2 million as compared to $2.3 million for the third quarter of 2020. Net loss included stock-based compensation expense of $0.8 million for the third quarter of 2021 and $21,000 for the third quarter of 2020.
Financial guidance: We expect that our cash and cash equivalents will be sufficient to fund our operations into the second half of 2025, based on our current operating plan.
About Aerovate Therapeutics
Aerovate is a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. Aerovate’s initial focus is on advancing AV-101, our dry powder inhaled formulation of the drug imatinib for the treatment of pulmonary arterial hypertension, or PAH. For more information, please visit www.aerovatetx.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements can be identified by words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “future,” “goal,” “intend,” “look forward to,” “may,” “plan,” “potential,” “predict,” “project,” “potential,” seek,” “strategy,” “should,” “target,” “will,” “would” and similar expressions regarding future periods. These forward-looking statements include, but are not limited to, statements regarding the therapeutic potential of AV-101; our expectations that we will initiate enrollment in the second half of 2021 for the Phase 2b portion of our Phase 2b/3 trial of AV-101 in PAH; our expectations of identifying clinical site locations and recruitment of patients for our Phase 2b/3 trial; our belief that we will have capital to fund Aerovate into the second half of 2025; our business plans and objectives for AV-101, including expectations regarding timing and success of the our Phase 2b/3 clinical trial, the therapeutic potential and clinical benefits of AV-101 and potential regulatory submissions and approvals for AV-101; and our growth as a company and the anticipated contribution of the members of our board of directors to our operations and progress.
Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the therapeutic potential of AV-101, and the timing associated with the identification of clinical sites, patient recruitment, initiation and continuation of our Phase 2b/3 trial of AV-101 in PAH patients, the impact of the COVID-19 pandemic on our business, clinical trials, operations and goals, positive results from a clinical study may not necessarily be predictive of the results of future or ongoing clinical studies, regulatory developments in the United States and foreign countries, and other risks identified in our filings with the Securities and Exchange Commission (“SEC”), including our Registration Statement on Form S-1, and subsequent filings with the SEC. We caution you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. We disclaim any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent our views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.
Aerovate Therapeutics, Inc.
Condensed Balance Sheets
|September 30,||December 31,|
|Cash and cash equivalents||$||180,878||$||4,573|
|Prepaid expenses and other current assets||2,224||103|
|Total current assets||183,102||4,676|
|Property and equipment, net||162||39|
|Operating lease right-of-use assets||583||-|
|Other long-term assets||278||-|
|Liabilities, Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit)|
|Accrued and other current liabilities||1,123||1,156|
|Operating lease liabilities||147||-|
|Total current liabilities||3,825||1,774|
|Operating lease liabilities, net of current portion||452||-|
|Commitments and contingencies|
|Series A redeemable convertible preferred stock||-||12,285|
|Series Seed redeemable convertible preferred stock||-||4,000|
|Stockholders’ equity (deficit):|
|Stockholders’ equity (deficit)||179,848||(13,344||)|
|Total liabilities, redeemable convertible preferred stock and stockholders’ equity (deficit)||$||184,125||$||4,715|
Aerovate Therapeutics, Inc.
Condensed Statements of Operations and Comprehensive Loss
(in thousands, except share and per share amounts)
|Three Months Ended September 30,||Nine Months Ended September 30,|
|Research and development||$||3,418||$||1,966||$||9,941||$||4,643|
|General and administrative||2,782||277||4,813||583|
|Total operating expenses||6,200||2,243||14,754||5,226|
|Loss from operations||(6,200||)||(2,243||)||(14,754||)||(5,226||)|
|Total other income (expense)||16||(64||)||14||(719||)|
|Net loss and comprehensive loss||$||(6,184||)||$||(2,307||)||$||(14,740||)||$||(5,945||)|
|Net loss per share, basic and diluted||$||(0.26||)||$||(10.13||)||$||(1.80||)||$||(25.20||)|
|Weighted-average shares of common stock outstanding, basic and diluted||23,885,017||242,901||8,180,359||241,949|